Comparison

Human CD20 Monoclonal Antibody, Endotoxin 0.05 EU/mg European Partner

Item no. YR0131-20mg
Manufacturer Abclonal
Amount 20 mg
Quantity options 20 mg 5 mg
Category
Applications ELISA, FA, NT
Specific against other
Isotype IgG1 Kappa
Purity >95% Determined by SDS-PAGE
NCBI CD20
Alias B1,S7,Bp35,CD20,FMC7,CVID5,LEU-16,MS4A1
Available
Manufacturer - Applications
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways
Manufacturer - Category
Biosimilar
Manufacturer - Conjugate / Tag
<5% Determined by SECP
Storage Conditions
2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)
Background
Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
Manufacturer - Cross Reactivity
<0.05EU/mg (<0.00005EU/μg)Determined by LAL gel clotting assay
Immunogen
Human CD20
Recommended Dilution
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Route
1×PBS pH 7.0
Manufacturer - Research Area
Cancer immunology
Gene Symbol
CD20

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 20 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close